Latest hyperglycemia Stories

2009-09-30 01:30:00

PARIS, September 30 /PRNewswire-FirstCall/ -- - 76% Higher Dose of Insulin detemir Needed to Achieve Similar, Well Tolerated Glycemic Control Versus Lantus(R) Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine [rDNA] injection) compared to twice-daily insulin detemir.

2009-09-09 09:39:40

Studies link improvements in diabetes control to frequency of use and demonstrate continued improvements 12 months after use, with 'remarkably low' occurrence of severe hypoglycemia.

2009-08-26 07:45:12

Mild glucose intolerance in pregnancy may be an early identifier of women who are at increased risk of heart disease in the future, according to a new Canadian study.

2009-07-30 06:30:30

Older diabetic patients who take antipsychotic medications appear to have an increased risk of hospitalization for hyperglycemia (elevated blood glucose level), especially soon after beginning treatment, according to a new report.

2009-06-24 12:25:00

Preliminary Data Demonstrates Reduction of HbA1c Levels With Doses an Order of Magnitude Lower than the Dose Used in the Current Phase 3 Trial. BETHESDA, Md., June 24 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq CM: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced positive preliminary results from a Phase 2 clinical trial of its...

2009-06-23 10:33:00

Kid Delegates Meet Elected Officials, Testify at Senate Hearing, and Urge Legislators To Request Fund Research WASHINGTON, June 23 /PRNewswire-USNewswire/ -- More than 150 children and teenagers throughout the U.S. with type 1 diabetes are in Washington, D.C.

2009-06-09 07:00:00

- SYNCHRONY Study Published in The Lancet Supports Cardio-Protective Potential of Aleglitazar - NUTLEY, N.J., June 9 /PRNewswire/ -- Roche today announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 which is uniquely designed to reduce cardiovascular morbidity and mortality in high risk patients with type 2 diabetes.

2009-06-06 10:00:00

- A1C and FBG Results for Patients 65 and Under Treated with Lantus and NPH were Similar - NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S.

2009-06-06 10:00:00

RIDGEFIELD, Conn., June 6 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced its pipeline of oral antidiabetic compounds, establishing itself in the type 2 diabetes therapeutic area.

2009-06-06 10:00:00

Two-year study presented at the American Diabetes Association's 69th Scientific Sessions shows investigational product comparable to standard insulin therapy in pulmonary function tests NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin with changes in pulmonary function tests comparable to usual antidiabetic treatment, according to data presented today at the American Diabetes Association's...

Word of the Day
  • A woman chauffeur.
  • A woman who operates an automobile.
The word 'chaffeuse' comes from French, and is the feminine form of 'chauffeur'.